The Barcelona-based firm, which has a protein splicing platform that aims to address the major limitation of delivering large genes using AAV vectors, has sealed the largest series A fundraising by a Spanish biotech.
Gene therapy is hardly flavor of the month for investors at the moment but that has not stopped SpliceBio from signing off the largest ever series A financing in Spain for a biotech company.
SpliceBio has completed an oversubscribed €50m finance round co-led by UCB Ventures and existing shareholder Ysios Capital. The latter has...
Public Company Edition: Sarepta restructured after stopping shipments of its Elevidys for some patients to ease future debt pressures, but now it has stopped shipments to all patients. Also, Madrigal secured up to $500m in new debt, Cogent closed a $230m offering and other financings.
Looking to improve on the efficacy and safety of Roche’s Esbriet and BI’s Ofev, Avalyn has inhalable formulations of those drugs in Phase IIb and Phase I, respectively.
The drugmaker plans to build a large manufacturing center in Virginia as the centerpiece of an effort to invest $50bn in the US by 2030.
